The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Derazantinib (DZB) in combination with atezolizumab (AZB) in patients with solid tumors: Results from the dose-finding phase Ib substudy of FIDES-02.
 
Raghad Muhsin Abdul-Karim
Research Funding - Adagene (Inst); Amphivena Therapeutics, Inc. (Inst); Basilea (Inst); Birdie (Inst); BJ Bioscience (Inst); Boston Biomedical (Inst); eFFECTOR Therapeutics (Inst); Gilead Sciences (Inst); InhibRx (Inst); ORIC Pharmaceuticals (Inst); Petra Pharma (Inst); Pfizer (Inst); Spring Bank (Inst); Synthorx (Inst); Takeda (Inst)
 
Arvind Chaudhry
Stock and Other Ownership Interests - Novartis
Speakers' Bureau - AstraZeneca; Bayer
 
Anna Patrikidou
No Relationships to Disclose
 
Alejandro Falcon Gonzalez
Consulting or Advisory Role - Roche
Speakers' Bureau - Lilly; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Lilly; Novartis; Pfizer; Roche
 
Fabricio Racca
Consulting or Advisory Role - Bristol-Myers Squibb
Speakers' Bureau - Bristol-Myers Squibb; Roche
Expert Testimony - Pharmore Research; Psyma
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme; Roche
 
Yohann Loriot
Honoraria - Pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Janssen; Janssen (Inst); MSD Oncology; MSD Oncology (Inst); Roche; Seagen
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); CureVac (Inst); Exelixis (Inst); Incyte (Inst); Janssen Oncology (Inst); Medivation (Inst); MSD Oncology (Inst); Nektar (Inst); Oncogenex (Inst); Pfizer (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Janssen Oncology; MSD Oncology; Roche; Seagen
 
Damien Pouessel
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen Oncology; Merck
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Janssen Oncology; Pfizer; Sanofi
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Janssen Oncology (Inst); Merck Sharp & Dohme (Inst); Roche (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Janssen Oncology; Pfizer
 
Jean-Laurent Deville
Honoraria - Bristol-Myers Squibb; Janssen Oncology; MSD Oncology
Consulting or Advisory Role - Bristol-Myers Squibb; Janssen Oncology; Sanofi
Speakers' Bureau - Astellas Pharma
 
Hyo Jin Lee
No Relationships to Disclose
 
Frederique Cantero
Employment - Basilea
 
Michalina Marszewska
Employment - Basilea
 
Mikael Saulay
Employment - Basilea
 
Stephan Braun
Employment - Basilea
Stock and Other Ownership Interests - Basilea
 
Rodryg Ramlau
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck; MSD Oncology; Novartis; Pfizer; Roche; Takeda
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Roche